NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA

被引：0
|
作者：
MacDiarmid, Scott
Martinson, Melissa
Black, Edward
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.1425
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1180
引用
收藏
页码：E478 / E478
页数：1
相关论文
共 50 条
  • [11] Cost-effectiveness of tolterodine, a new treatment for symptoms of overactive bladder.
    Kobelt, G
    Jonsson, L
    Lund, AM
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05): : 302 - 302
  • [12] COST-EFFECTIVENESS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER IN ARGENTINA
    Ramos, B.
    Sanchez Trujillo, L. A.
    Walker, D.
    Anaya, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S378 - S378
  • [13] Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden
    Prutz, C.
    Snedecor, S.
    Botteman, M.
    Trocio, J.
    Weinstein, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [14] Cost-effectiveness of novel therapies for overactive bladder
    Mayr, Craig A.
    Shepherd, Jonathan P.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
  • [15] COST-EFFECTIVENESS STUDY OF DIAGNOSTIC TOOLS FOR THE EVALUATION OF FEMALE WITH OVERACTIVE BLADDER SYMPTOMS
    Lopez-Fando Lavalle, L.
    Jimenez Cidre, M. A.
    Esteban Fuertes, M.
    Prieto Chaparro, L.
    Arlandis Guzman, S.
    Franco de Castro, A.
    Salinas Casado, J.
    Castro-Diaz, D.
    Gutierrez Ruiz, C.
    Ifu, G.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2012, 31 (06) : 1007 - 1008
  • [16] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Parise, Helene
    Espinosa, Robert
    Dea, Katherine
    Anaya, Pablo
    Montoya, Giovanny
    Bin Ng, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2020, 4 (01) : 79 - 90
  • [17] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Hélène Parise
    Robert Espinosa
    Katherine Dea
    Pablo Anaya
    Giovanny Montoya
    Daniel Bin Ng
    [J]. PharmacoEconomics - Open, 2020, 4 : 79 - 90
  • [18] The cost utility of solifenacin in the treatment of overactive bladder
    Hakkaart, Leona
    Verboom, Paul
    Phillips, Richard
    Al, Maiwenn J.
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2009, 41 (02) : 293 - 298
  • [19] The cost utility of solifenacin in the treatment of overactive bladder
    Leona Hakkaart
    Paul Verboom
    Richard Phillips
    Maiwenn J. Al
    [J]. International Urology and Nephrology, 2009, 41 : 293 - 298
  • [20] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Jonathan P. Shepherd
    Charelle M. Carter-Brooks
    Christopher Chermanksy
    [J]. International Urogynecology Journal, 2018, 29 : 1213 - 1219
12345